NRD
PACB icon

Nebula Research & Development’s Pacific Biosciences PACB Stock Holding History

Nebula Research & Development’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-106,434
Closed -$399K – 983
2024
Q1 		$399K Buy
+106,434
New +$623K 0.09% 432
2023
Q4 		– Sell
-19,596
Closed -$164K – 826
2023
Q3 		$164K Buy
+19,596
New +$224K 0.09% 422

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's PACB Position: Q2 2024 in Review

Nebula Research & Development sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 106,434 shares — an estimated $399K sold.

Nebula Research & Development first reported a position in PACB in Q3 2023 and held it in 2 quarters. The position peaked at $399K in Q1 2024. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Nebula Research & Development reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 106,434 Pacific Biosciences shares in Q2 2024, an estimated $399K.
  • Nebula Research & Development first reported a position in Pacific Biosciences in Q3 2023 and held it in 2 quarters.
  • Nebula Research & Development's Pacific Biosciences position peaked at $399K in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.